Suchergebnisse - "Blagden, Sarah P"

PubPharm (65)

1

A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301)

enthalten in: Journal of experimental & clinical cancer research : CR | 2024

von Spiliopoulou, P. | Kazmi, F. | Aroldi, F. | +12

2

A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301)

enthalten in: Journal of experimental & clinical cancer research | 2024

von Spiliopoulou, P. | Kazmi, F. | Aroldi, F. | +12

3

A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors

enthalten in: Cancers | 2024

von Janku, F. | Choong, G. | Opyrchal, M. | +12

4

Cancer Precision-Prevention trial of Metformin in adults with Li Fraumeni syndrome (MILI) undergoing yearly MRI surveillance : a randomised controlled trial protocol

enthalten in: Trials | 2024

von Dixon-Zegeye, M. | Shaw, R. | Collins, L. | +15

5

Cancer Precision-Prevention trial of Metformin in adults with Li Fraumeni syndrome (MILI) undergoing yearly MRI surveillance: a randomised controlled trial protocol

enthalten in: Trials | 2024

von Dixon-Zegeye, M. | Shaw, R. | Collins, L. | +15

6

Subcellular mRNA localization regulates ribosome biogenesis in migrating cells

enthalten in: bioRxiv.org | 2023

von Dermit, M. | Dodel, M. | Lee, F. | +6

7

Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors

enthalten in: British journal of cancer | 2023

von Luke, J. | Fakih, M. | Schneider, C. | +12

8

From the European Medicines Agency to Project Orbis : new activities and challenges to facilitate UK oncology drug approval following Brexit

enthalten in: The Lancet. Oncology | 2023

von Lythgoe, M. | Krell, J. | Bower, M. | +5

9

Additional consensus recommendations for conducting complex innovative trials of oncology agents : a post-pandemic perspective

enthalten in: British journal of cancer | 2023

von Blagden, S. | Yu, L. | Ellis, S. | +10

10

First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors

enthalten in: Journal for immunotherapy of cancer | 2022

von Davis, E. | Martin-Liberal, J. | Kristeleit, R. | +15

1
2
3
4
5
6
7
Nächster »
[7]